文章摘要
杨文杰,梁妍,李洁,马彦民,李宁,孙定勇,王哲.复方新诺明预防治疗对艾滋病患者生存状况的影响[J].中华流行病学杂志,2014,35(6):689-694
复方新诺明预防治疗对艾滋病患者生存状况的影响
Effect of co-trimoxazole prophylaxis used for AIDS patients under anti-retroviral therapy
收稿日期:2013-10-22  出版日期:2014-09-02
DOI:
中文关键词: 艾滋病;复方新诺明;抗病毒治疗;生存分析
英文关键词: Acquired immunodeficiency syndrome;Co-trimoxazole;Antiretroviral therapy; Survival analysis
基金项目:国家科技重大专项(2012ZX10004905)
作者单位E-mail
杨文杰 450016 郑州, 河南省疾病预防控制中心性病艾滋病防治研究所  
梁妍 450016 郑州, 河南省疾病预防控制中心性病艾滋病防治研究所  
李洁 450016 郑州, 河南省疾病预防控制中心性病艾滋病防治研究所  
马彦民 450016 郑州, 河南省疾病预防控制中心性病艾滋病防治研究所  
李宁 450016 郑州, 河南省疾病预防控制中心性病艾滋病防治研究所  
孙定勇 450016 郑州, 河南省疾病预防控制中心性病艾滋病防治研究所  
王哲 450016 郑州, 河南省疾病预防控制中心性病艾滋病防治研究所 wangzhe@hncdc.com.cn 
摘要点击次数: 2232
全文下载次数: 1133
中文摘要:
      目的 了解复方新诺明(CTX)预防治疗对河南省接受国家免费抗病毒治疗(ART)的艾滋病患者生存状况的影响。方法 利用“中国疾病预防控制系统-艾滋病综合防治信息系统”收集的河南省2007-2011 年加入国家免费ART艾滋病患者资料,根据开始接受ART时既往CTX使用情况,将研究对象分为既往未服用、既往服用过现仍服用和既往服用过现未服用3 组,采用Kaplan-Meier 法绘制生存曲线,运用Cox比例风险回归模型分析CTX预防治疗对艾滋病患者生存状况的影响。结果 13 103 名艾滋病患者中共有1 702 名死亡,死亡率为4.46/100 人年,开始治疗3 个月和12 个月内分别死亡455 人和970 人,死亡率分别为14.15/100 人年和7.78/100 人年。开始ART时既往未服用、既往服用过现仍服用和既往服用过现未服用CTX三组中以既往服用过现仍服用组的生存期(M=0.98 年,IQR:0.25~2.16)最长,Kaplan-Meier 生存曲线显示,开始治疗时既往服用过现仍服用CTX 组生存时间长于既往未服用CTX 组,死亡率低于既往未服用CTX 组,log-rank 检验显示,开始治疗12 个月内的两组间差异有统计学意义(log-rank=5.15,P=0.02)。多因素分析发现,研究对象开始治疗时年龄、性别、婚姻状况、传播途径、确认阳性到开始治疗的时间、基线CD4T 淋巴细胞计数、临床分期、初始治疗方案、CTX服用情况、开始治疗时年份、基线症状数、最近7 d 是否漏服与生存时间存在统计学关联,其中既往使用过现仍服用CTX组的死亡风险低于既往未服用CTX组(调整HR=0.71,95%CI:0.63~0.80,P=0.00)。结论 艾滋病ART开始时既往CTX预防治疗可以降低艾滋病患者的死亡风险,特别是在开始治疗的第1 年内效果明显。
英文摘要:
      Objective To analyze the situation of survival among AIDS patients under cotrimoxazole prophylaxis as initial anti-retroviral therapy(ART),in Henan province during 2007-2011. Methods Information on AIDS patients receiving initial ART during 2007-2011 was collected from the Chinese HIV/AIDS Integrated Control System. Kaplan-Meier estimation was used to generate survival curves,and Cox proportional hazard regression model was used to determine associated factors of survival status. According to the previous CTX use before ART,the subjects were divided into 3 groups including who had never taken CTX,who had taken CTX and still taking now,who had taken CTX and not current taking. Results A total of 13 103 eligible AIDS patients were identified. 1 702 patients died within 6 years after the initiation of ART,with the mortality as 4.46/100 person year. Among the 455 patients who died within 3 months and 970 died within 12 months,the mortality rates were 14.15/100 person year and 7.78/100 person year,respectively. The Kaplan-Meier survival curves showed that the survival time and mortality of the patients who had taken CTX was longer AND lower than those patients who had never taken CTX when starting the ART program. Results from the log-rank test showed that the difference of two groups was statistically significant during 12 months after the ART(log-rank=5.15,P=0.02). After controlling for other variables,results from multivariable analysis of COX model showed that factors as age,gender,marital status,perion between confirmed diagnosis and receiving the ART,baseline CD4 T cells count,clinical stage,initial therapy schedule,date when starting the ART,number of symptoms at baseline,use of CTX before starting the ART and ART being skipped in the last seven days etc,were associated with the time of survival in patients after the initiation of ART. Patients who had been taking CTX at ART initiation were at lower risk of death (adjusted HR=0.71,95% CI:0.63-0.80;P=0.00),compared to those who had never taken the CTX. Conclusion The co-trimoxazole prophylaxis program was associated with the reduced mortality among AIDS patients who were on ART in Henan province,especially during the first year.
查看全文   Html全文     查看/发表评论  下载PDF阅读器
关闭